Yahoo•2026-04-22
CVS Health (CVS) Stock Falls Amid Market Uptick: What Investors Need to KnowCVS — CVS Health Corp
NYSE · Health Care · Health Care
$76.43-4.09%Market cap 93.49B
- Latest Close
- $76.43
- 30-Day Move
- -4.1%
- Market Cap
- $93.5B
- Shares Outstanding
- 1,272,210,000
- P/E Ratio
- 52.88
- P/B Ratio
- 1.34
Analyst consensus: Buy · 33 analysts
NYSE:CVSHealth Care / Health CareDelayed public snapshot
CVS Health Corp
A read-only Alphactor snapshot for CVS Health Corp. It uses the same research structure as the app, but with delayed data and shallow depth so search visitors can evaluate the stock before signing up.
Snapshot as of 2026-04-22
Topline snapshot
Latest Close
$76.43
30-Day Move
-4.1%
Market Cap
$93.5B
Shares Outstanding
1,272,210,000
P/E Ratio
52.88
P/B Ratio
1.34
Not investment advice. Signals and scores shown here are model outputs derived from historical data, not recommendations. Past performance does not guarantee future results. Do your own research before trading. Full disclaimer
Chart snapshot
$76.43
-4.1%last 90 delayed daily bars
Market cap $93.5B
90D High
$84.00
90D Low
$69.51
Avg Volume
8,103,817
What stands out
Gross margin is running at 13.8%, which gives a quick read on operating quality before you open the full model.
Net margin is 44.0%, useful for comparing CVS against peers in Health Care.
CVS is down 4.1% over the last 30 trading days shown on this page.
Latest operating income is $10.4B, which helps anchor the headline ratios with an actual earnings figure.
Research snapshot
Composite Fair Value
$549.64
Rule of 40
9.8%
Dark Pool Short %
58.8%
Fundamentals snapshot
Latest Close
$76.43
30-Day Move
-4.1%
Market Cap
$93.5B
Shares Outstanding
1,272,210,000
P/E Ratio
52.88
P/B Ratio
1.34
ROE
2.4%
ROA
70.0%
Gross Margin
13.8%
Operating Margin
1.3%
Net Margin
44.0%
Debt / Equity
0.86
Current Ratio
0.84
Dividend Yield
3.8%
Latest Revenue
$402.1B
Financial statement snapshot
Revenue
$402.1B
Gross Profit
$55.4B
Operating Income
$10.4B
Net Income
$1.8B
Gross Margin
1377.0%
Net Margin
44.0%
Current Ratio
0.84
Debt / Equity
0.86
Valuation snapshot
Fair Value
$549.64
Upside / Downside
+619.1%
Signal
Undervalued
Implied Growth
5.3%
DCF
$72.17
EPV
$52.77
EV/Rev
$1523.99
Growth Assumption
7.6%
Discount Rate
8.2%
Terminal Growth
2.0%
Base FCF
$7.8B
Valuation spread
Current Price
$76.43
Composite Fair Value
$549.64
DCF
$72.17
EPV
$52.77
EV/Rev
$1523.99
After signup
The full valuation workspace goes deeper
Adjust DCF growth, discount, and terminal assumptions instead of relying on one static snapshot.
Open the deeper balance-sheet and cash-flow views to inspect debt, liquidity, and cash generation line by line.
Compare multiple valuation models against peers and save your own thesis instead of re-reading a fixed public state.
Low growth priced in
Quality snapshot
Altman Z
2.31
Grey
Piotroski
7
Strong (7-9)
Cash Conversion
6.02x
Rule of 40
9.8%
Concerning
Annual financial history
Annual performance mix
| Period | Revenue | Operating Income | Net Income | Free Cash Flow |
|---|---|---|---|---|
| 2022-12-31 | $322.5B | $16.3B | $4.3B | $13.4B |
| 2023-12-31 | $357.8B | $14.6B | $8.3B | $10.4B |
| 2024-12-31 | $372.8B | $9.7B | $4.6B | $6.3B |
| 2025-12-31 | $402.1B | $10.4B | $1.8B | $7.8B |
After signup
The app opens the full statement deep dive
Extend the history well beyond this public snapshot to inspect longer cycles and regime changes.
Move from summary lines into detailed balance-sheet and cash-flow rows for working capital, debt, and capex analysis.
Cross-link statement changes with alerts, watchlists, and saved research workflows after signup.
News snapshot
Yahoo•2026-04-22
How UNH Stock Is Trading Short-Term Margins For Long-Term MoatsYahoo•2026-04-22
Is CVS Health the Ultimate Value Stock to Buy Right Now?Finnhub•2026-04-22
Coram CVS Specialty Infusion Services Uses New Sustainable PackagingYahoo•2026-04-22
UnitedHealth Boosts Profit Forecast Without Committing to Medicare Obesity Drug CoverageAfter signup
The full sentiment workspace adds context
Go past the public headlines into fuller article history, source cross-checks, and deeper narrative tracking.
Tie news into alerts, watchlists, and conviction changes instead of browsing one static batch of stories.
ETF holders snapshot
| ETF | Shares | Weight | As Of |
|---|---|---|---|
| Dodge & Cox Funds-Dodge & Cox Stock Fund | 41,991,204 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 39,892,960 | 0.03% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard 500 Index Fund | 32,012,375 | 0.03% | 2025-12-31 |
| WASHINGTON MUTUAL INVESTORS FUND | 31,734,083 | 0.02% | 2026-03-31 |
| Income Fund of America | 23,692,996 | 0.02% | 2026-01-31 |
| AMERICAN BALANCED FUND | 18,524,992 | 0.01% | 2025-12-31 |
| Fidelity Concord Street Trust-Fidelity 500 Index Fund | 16,155,114 | 0.01% | 2026-02-28 |
| iShares Trust-iShares Core S&P 500 ETF | 16,182,338 | 0.01% | 2026-02-28 |
After signup
The deeper ownership view shows who is leaning in
Open richer institutional and holder diffs to see position changes across filings instead of one static snapshot.
Use those ownership shifts alongside conviction and alerts in the full app workflow.
Institutional holders snapshot
Two Sigma Advisers
Filed 2025-05-15
--
--
Vanguard Group
Filed 2026-01-29
$9.6B
+1.5%
BlackRock
Filed 2024-05-10
$6.9B
--
FMR LLC (Fidelity)
Filed 2026-02-17
$3.3B
-5.3%
Geode Capital Management
Filed 2026-02-09
$2.3B
+0.2%
Invesco
Filed 2026-02-19
$1.9B
-1.1%
Dark-pool activity snapshot
Analyst consensus?
Rating(?)
4.03
Consensus
BuyTarget Mean(?)
—
Target High(?)
—
Target Low(?)
—
Analysts
33
For informational and educational purposes only. Not financial advice. Learn more
Related reading
Research and strategy guides from the alphactor blog.
Healthcare Investing: Pharma, Biotech, and the FDA Calendar
A framework for navigating healthcare stocks across pharma, biotech, and medical devices, with emphasis on regulatory catalysts and pipeline valuation.
Accruals Quality: How to Spot Earnings That Aren't Real
Accruals measure the gap between reported earnings and actual cash. Widening accruals is one of the most reliable red flags in financial analysis — Sloan's…
Altman Z-Score: A Bankruptcy Predictor That Still Works
Edward Altman's 1968 discriminant model predicts bankruptcy within two years about 72% of the time at its distress threshold.